Aug 8 (Reuters)-
Brightpath Biotherapeutics Co., Ltd.
PARENT-ONLY FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
3 months ended 3 months ended Year to
Jun 30, 2025 Jun 30, 2024 Mar 31, 2026
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 0 mln 0 mln 0 mln
(+20.0 pct) (+66.7 pct) (-87.6 pct)
Operating loss 245 mln loss 326 mln loss 1.18
Recurring loss 240 mln loss 329 mln loss 1.16
Net loss 241 mln loss 330 mln loss 1.17
EPS loss 2.59 yen loss 4.66 yen loss 12.88 yen
Ann Div NIL NIL
-Q2 div NIL NIL
-Q4 div NIL NIL
NOTE - Brightpath Biotherapeutics Co., Ltd..
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4594.T